These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

841 related articles for article (PubMed ID: 25625928)

  • 1. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
    Kirner A; Mayer-Mokler A; Reinhardt C
    Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy.
    Rausch S; Kruck S; Stenzl A; Bedke J
    Future Oncol; 2014 May; 10(6):937-48. PubMed ID: 24941980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.
    Walter S; Weinschenk T; Stenzl A; Zdrojowy R; Pluzanska A; Szczylik C; Staehler M; Brugger W; Dietrich PY; Mendrzyk R; Hilf N; Schoor O; Fritsche J; Mahr A; Maurer D; Vass V; Trautwein C; Lewandrowski P; Flohr C; Pohla H; Stanczak JJ; Bronte V; Mandruzzato S; Biedermann T; Pawelec G; Derhovanessian E; Yamagishi H; Miki T; Hongo F; Takaha N; Hirakawa K; Tanaka H; Stevanovic S; Frisch J; Mayer-Mokler A; Kirner A; Rammensee HG; Reinhardt C; Singh-Jasuja H
    Nat Med; 2012 Aug; 18(8):1254-61. PubMed ID: 22842478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
    Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
    Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma.
    Buchner A; Pohla H; Willimsky G; Frankenberger B; Frank R; Baur-Melnyk A; Siebels M; Stief CG; Hofstetter A; Kopp J; Pezzutto A; Blankenstein T; Oberneder R; Schendel DJ
    Hum Gene Ther; 2010 Mar; 21(3):285-97. PubMed ID: 19788391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?
    Bedke J; Stenzl A
    Expert Rev Anticancer Ther; 2013 Dec; 13(12):1399-408. PubMed ID: 24215158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IMA901: a peptide vaccine in renal cell carcinoma.
    Bedke J; Stenzl A
    Expert Opin Investig Drugs; 2013 Oct; 22(10):1329-36. PubMed ID: 23899354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
    Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine.
    Zhou X; Jun DY; Thomas AM; Huang X; Huang LQ; Mautner J; Mo W; Robbins PF; Pardoll DM; Jaffee EM
    Cancer Res; 2005 Feb; 65(3):1079-88. PubMed ID: 15705910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II study of multipeptide cancer vaccine IMA901 after single-dose cyclophosphamide in Japanese patients with advanced renal cell cancer with long-term follow up.
    Hongo F; Ueda T; Takaha N; Tamada S; Nakatani T; Miki T; Ukimura O
    Int J Urol; 2023 Feb; 30(2):176-180. PubMed ID: 36305687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer.
    Aruga A; Takeshita N; Kotera Y; Okuyama R; Matsushita N; Ohta T; Takeda K; Yamamoto M
    Clin Cancer Res; 2013 Apr; 19(8):2224-31. PubMed ID: 23479678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TroVax in colorectal cancer.
    Rowe J; Cen P
    Hum Vaccin Immunother; 2014; 10(11):3196-200. PubMed ID: 25483641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma.
    Combe P; de Guillebon E; Thibault C; Granier C; Tartour E; Oudard S
    Oncoimmunology; 2015 May; 4(5):e1001236. PubMed ID: 26155388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses.
    Zhou J; Weng D; Zhou F; Pan K; Song H; Wang Q; Wang H; Wang H; Li Y; Huang L; Zhang H; Huang W; Xia J
    Cancer Immunol Immunother; 2009 Oct; 58(10):1587-97. PubMed ID: 19221746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial.
    Baek S; Kim CS; Kim SB; Kim YM; Kwon SW; Kim Y; Kim H; Lee H
    J Transl Med; 2011 Oct; 9():178. PubMed ID: 22013914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine.
    Block MS; Suman VJ; Nevala WK; Kottschade LA; Creagan ET; Kaur JS; Quevedo JF; McWilliams RR; Markovic SN
    Melanoma Res; 2011 Oct; 21(5):438-45. PubMed ID: 21697748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
    Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
    J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.